STOCK TITAN

InMed hires Deloitte & Touche LLP as FY2026 auditor

Available on EDGAR Accepted by SEC EDGAR Learn about SEC filing dates
(Moderate)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Form Type
8-K

Rhea-AI Filing Summary

InMed Pharmaceuticals Inc. (INM), identified after the merger as Mentari Therapeutics, Inc., dismissed CBIZ CPAs P.C. on November 17, 2026, and Ernst & Young LLP with respect to Mentari’s financial statements. The Audit Committee approved both dismissals. CBIZ’s reports on InMed’s fiscal years ended June 30, 2026 and 2025 included an explanatory paragraph stating substantial doubt about InMed’s ability to continue as a going concern. EY’s report on Mentari’s financial statements as of December 31, 2025 and for the period beginning June 13, 2025 included a similar paragraph.

Deloitte & Touche LLP was engaged on November 19, 2026, for the fiscal year ending December 31, 2026. The company reported no qualifying disagreements or reportable events with either outgoing firm during the respective periods described, and no consultations with Deloitte on the specified accounting, audit-opinion, disagreement or reportable-event matters. The November 6, 2026 merger was accounted for as a reverse recapitalization, with Mentari treated as the accounting acquirer.

0 points · 0 major

How this balance works

Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.

It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.

Rhea-AI Sentiment measures something else, the tone of the wording.

1 major · 1 point

How the balance works

Positive

  • None.

Negative

  • Major pointPrior auditor reports included substantial doubt about InMed’s and Mentari’s ability to continue as going concerns.
Item 4.01 Changes in Registrant's Certifying Accountant Governance
The company changed its independent auditing firm, which may involve disagreements on accounting matters.
Item 9.01 Financial Statements and Exhibits Exhibits
Financial statements, pro forma financial information, or exhibit attachments filed with this report.
reverse recapitalization financial
"accounted for as a reverse recapitalization"
A reverse recapitalization is a way for a privately held company to become publicly traded by taking control of an existing public company and swapping ownership rather than going through a traditional public offering. For investors it matters because it can quickly change who controls a company and reshape its share structure and value — like a homeowner swapping houses and keys rather than building a new one — so it can create sudden shifts in stock supply, dilution and market expectations.
going concern financial
"substantial doubt about InMed’s ability to continue as a going concern"
Going concern is the accounting assumption that a company will keep operating and meeting its obligations for the foreseeable future. The phrase matters most when a company or its auditors disclose substantial doubt about it, a formal warning that the business may not have enough resources to continue without raising money, restructuring, or selling assets. That language in a filing or press release signals elevated financial risk.
reportable events regulatory
"there were no “reportable events”"
Reportable events are significant incidents or changes a company is legally required to disclose to regulators and the public, such as major safety problems, legal actions, financial irregularities, or management changes. They matter to investors because these events can alter a company’s risk profile or future performance, much like a dashboard warning light signals a problem that could affect a car’s safety or reliability. Timely disclosure helps investors make informed decisions and maintain market fairness.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

Who is INM’s independent auditor for fiscal 2026?

Deloitte & Touche LLP is the company’s independent registered public accounting firm for the fiscal year ending December 31, 2026; the Audit Committee approved the engagement on November 19, 2026.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
NASDAQ false 0001728328 0001728328 2026-11-17 2026-11-17
 
 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

Pursuant to Section 13 OR 15(d)

of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): November 17, 2026

 

 

Mentari Therapeutics, Inc.

(Exact name of Registrant as specified in its charter)

 

 

 

Nevada   001-39685   98-1428279
(State or other jurisdiction
of incorporation)
 

(Commission

File Number)

  (IRS Employer
Identification No.)

 

221 Crescent Street, Building 23, Suite 105,  
Waltham, MA   02453
(Address of principal executive offices)   (Zip Code)

Registrant’s telephone number, including area code: (781) 887-5080

N/A

(Former name or former address, if changed since last report)

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

☐

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

☐

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

☐

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

☐

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

 

Trading

Symbol(s)

 

Name of each exchange

on which registered

Common Stock, par value $0.0001 per share   MTRI   The Nasdaq Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 
 


As previously reported, on November 6, 2026, Mentari Therapeutics, Inc., a Nevada corporation formerly known as InMed Pharmaceuticals Inc. (the “Company” and, with respect to periods prior to the closing of the Merger (as defined below), “InMed”), completed its business combination with Mentari Therapeutics, Inc., a Delaware corporation (“Mentari”), pursuant to the Agreement and Plan of Merger and Reorganization, dated as of May 19, 2026, as amended on July 6, 2026, by and among InMed, Indigo Merger Sub Corp., Indigo Merger Sub II, LLC and Mentari, pursuant to which Indigo Merger Sub Corp. merged with and into Mentari, with Mentari surviving as a wholly owned subsidiary of the Company, and, immediately thereafter, Mentari merged with and into Indigo Merger Sub II, LLC, with Indigo Merger Sub II, LLC surviving as a wholly owned subsidiary of the Company and changing its name to “Mentari Therapeutics Operating Company LLC” (collectively, the “Merger”). For accounting purposes, the Merger was accounted for as a reverse recapitalization, with Mentari treated as the accounting acquirer. As such, the historical financial statements of Mentari became the historical financial statements of the Company.

Item 4.01 Changes in Registrant’s Certifying Accountant.

(a) Dismissal of Independent Registered Public Accounting Firms

CBIZ

CBIZ CPAs P.C. (“CBIZ”) served as the independent registered public accounting firm of InMed prior to the consummation of the Merger. On November 17, 2026, CBIZ was dismissed as the independent registered public accounting firm of the Company. The decision to dismiss CBIZ was approved by the Audit Committee of the Company’s Board of Directors (the “Audit Committee”).

Except for an explanatory paragraph stating that substantial doubt exists about InMed’s ability to continue as a going concern, the reports of CBIZ on the consolidated financial statements of InMed for the fiscal years ended June 30, 2026 and 2025 did not contain an adverse opinion or disclaimer of opinion and were not qualified or modified as to uncertainty, audit scope or accounting principles.

During InMed’s fiscal years ended June 30, 2026 and 2025 and the subsequent interim period through November 17, 2026, (i) there were no disagreements (as defined in Item 304(a)(1)(iv) of Regulation S-K and the related instructions) with CBIZ on any matter of accounting principles or practices, financial statement disclosure, or auditing scope or procedure, which disagreements, if not resolved to CBIZ’s satisfaction, would have caused CBIZ to make reference thereto in its reports on InMed’s financial statements for such periods, and (ii) there were no “reportable events” (as defined in Item 304(a)(1)(v) of Regulation S-K).

The Company provided CBIZ with a copy of the disclosures made in this Item 4.01 and requested CBIZ to furnish the Company with a letter addressed to the U.S. Securities and Exchange Commission (the “SEC”) stating whether it agrees with the statements made by the Company and, if not, stating the respects in which it does not agree. A copy of CBIZ’s letter to the SEC dated November 19, 2026 regarding these statements is filed as Exhibit 16.1 to this Current Report on Form 8-K.

EY

Ernst & Young LLP (“EY”) served as the independent registered public accounting firm of Mentari prior to the consummation of the Merger. On November 17, 2026, EY was dismissed as the independent registered public accounting firm of the Company with respect to the financial statements of Mentari. The decision to dismiss EY was approved by the Audit Committee.

Except for an explanatory paragraph stating that substantial doubt exists about Mentari’s ability to continue as a going concern, the report of EY on the financial statements of Mentari as of December 31, 2025 and for the period from June 13, 2025 (inception) to December 31, 2025 did not contain an adverse opinion or disclaimer of opinion and was not qualified or modified as to uncertainty, audit scope or accounting principles.

During the period from June 13, 2025 (inception) to December 31, 2025 and the subsequent interim period through November 17, 2026, (i) there were no disagreements (as defined in Item 304(a)(1)(iv) of Regulation S-K and the

 


related instructions) with EY on any matter of accounting principles or practices, financial statement disclosure, or auditing scope or procedure, which disagreements, if not resolved to EY’s satisfaction, would have caused EY to make reference thereto in its report on Mentari’s financial statements for such period, and (ii) there were no “reportable events” (as defined in Item 304(a)(1)(v) of Regulation S-K).

The Company provided EY with a copy of the disclosures made in this Item 4.01 and requested EY to furnish the Company with a letter addressed to the SEC stating whether it agrees with the statements made by the Company and, if not, stating the respects in which it does not agree. A copy of EY’s letter to the SEC dated November 19, 2026 regarding these statements is filed as Exhibit 16.2 to this Current Report on Form 8-K.

(b) Engagement of New Independent Registered Public Accounting Firm

On November 19, 2026, the Company engaged Deloitte & Touche LLP (“Deloitte”) as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026. The engagement of Deloitte was approved by the Audit Committee. During InMed’s fiscal years ended June 30, 2026 and 2025, the period from June 13, 2025 (inception) to December 31, 2025 and the subsequent interim period through November 17, 2026, none of InMed, Mentari, the Company or anyone on their behalf consulted with Deloitte regarding either (i) the application of accounting principles to a specified transaction, either completed or proposed, or the type of audit opinion that might be rendered on the financial statements of InMed, Mentari or the Company, and neither a written report nor oral advice was provided to InMed, Mentari or the Company that Deloitte concluded was an important factor considered by InMed, Mentari or the Company in reaching a decision as to any accounting, auditing or financial reporting issue, or (ii) any matter that was the subject of a disagreement (as defined in Item 304(a)(1)(iv) of Regulation S-K and the related instructions) or a reportable event (as defined in Item 304(a)(1)(v) of Regulation S-K).

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

 

Exhibit No.   

Description

16.1    Letter from CBIZ CPAs P.C. to the U.S. Securities and Exchange Commission, dated November 19, 2026.
16.2    Letter from Ernst & Young LLP to the U.S. Securities and Exchange Commission, dated November 19, 2026.
104    Cover Page Interactive Data File (embedded within the Inline XBRL document).

 


SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  Mentari Therapeutics, Inc.
  (Registrant)  
Date: November 19, 2026   By:  

/s/ Jerad G. Seurer

    Name:   Jerad G. Seurer
    Title:   General Counsel and Corporate Secretary

Filing Exhibits & Attachments

5 documents

Keep reading